And that doesn’t take into account we are relatively close to being paid $750m USD milestones, $30m USD voucher money, and royalties. I think NEU would need $1bn USD to square those monies away.
Then our current MC and then a takeover premium as an opening bid.
With Baker Bros lazy $19bn balance sheet, they have the grunt to do this deal. They might bring in a hedge fund to help out.
Anybody who remembers Shire Pharmaceuticals will know the value here. Especially post Angelmans and new indications from animal trials.
It’s hard to imagine ACAD saying we have identified opportunities to grow but will need a lot of capital, then pursuing another drug. Neurology drugs are notoriously risky . So they know just how rare NNZ2591 really is.
And that doesn’t take into account we are relatively close to...
-
- There are more pages in this discussion • 225 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.59 |
Change
0.380(2.50%) |
Mkt cap ! $1.992B | |||
| Open | High | Low | Value | Volume |
| $15.51 | $15.82 | $15.46 | $11.26M | 722.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 696 | $15.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.67 | 6942 | 8 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |